X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders
X4 Pharmaceuticals will host a virtual Investor Day on October 29, 2026, discussing the development of mavorixafor, an oral CXCR4 antagonist in late-stage trials for treating chronic neutropenia. The event features management updates on the Phase 3 4WARD trial, plans for a Phase 2 trial combining mavorixafor with G-CSF, and presentations by hematol…